Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Nov 16, 2022--
The "Inhibitor of Apoptosis (IAP) Antagonist - Pipeline Insight, 2022" report has been added to ResearchAndMarkets.com's offering.
This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Inhibitor of Apoptosis (IAP) Antagonist commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inhibitor of Apoptosis (IAP) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Inhibitor of Apoptosis (IAP) Antagonist R&D. The therapies under development are focused on novel approaches to treat/improve Inhibitor of Apoptosis (IAP) Antagonist.
Inhibitor of Apoptosis (IAP) Antagonist Emerging Drugs Chapters
This segment of the Inhibitor of Apoptosis (IAP) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Inhibitor of Apoptosis (IAP) Antagonist Emerging Drugs
Xevinapant: Debiopharm/Merck
Xevinapant, now under an exclusive license agreement with Merck for product development and commercialization, is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins). As leader of the class of IAP inhibitors, xevinapant established proof of efficacy in high-risk locally advanced squamous cell carcinoma of the head and neck (LASCCHN) patients for which the combination provided highly significant and sustainable clinical benefit as compared to CRT alone.
In addition to combination with CRT, xevinapant is also being investigated in combination with chemotherapy as well as checkpoint inhibitors. The IAPs work to help tumor cells to escape from this controlled, cell death pathway and thus survive and proliferate. By inhibiting IAPs, Xevinapant enhances the killing of cancer cells by CRT, facilitating the destruction of the tumor.
In addition, pre-clinical studies have shown a direct enhancement T lymphocyte activation, revealing the compound's dual mode of action. An exclusive license agreement has been granted to Merck in 2021 for its further development and commercialization.
ASTX 660: Astex Pharmaceuticals
Tolinapant is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance.
By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism which works to enhance an anti-tumor immune response in T-cell lymphomas. Tolinapant was designed using Astex's fragment-based drug design technology.
Inhibitor of Apoptosis (IAP) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Inhibitor of Apoptosis (IAP) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Inhibitor Of Apoptosis (IAP) Antagonist
There are approx. 6+ key companies which are developing the therapies for Inhibitor of Apoptosis (IAP) Antagonist. The companies which have their Inhibitor of Apoptosis (IAP) Antagonist drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.
Phases
This report covers around 6+ products under different phases of clinical development like
Inhibitor of Apoptosis (IAP) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Inhibitor of Apoptosis (IAP) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inhibitor of Apoptosis (IAP) Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inhibitor of Apoptosis (IAP) Antagonist drugs.
Inhibitor of Apoptosis (IAP) Antagonist Report Insights
Inhibitor Of Apoptosis (IAP) Antagonist Report Assessment
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
For more information about this report visit https://www.researchandmarkets.com/r/854mhf
View source version on businesswire.com:https://www.businesswire.com/news/home/20221116005546/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/16/2022 06:05 AM/DISC: 11/16/2022 06:06 AM
http://www.businesswire.com/news/home/20221116005546/en